Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway

Hepatocellular carcinoma (HCC) is a high mortality liver cancer. The existing treatments (transplantation, chemotherapy, and individualized treatment) with limitations. However, drug combination provides a viable option for hepatocellular carcinoma treatment. A Chinese patent medicine, ShuangDan Cap...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Wenbo, Chen, Xiuwei, Yang, Licheng, Chen, Yaping, Song, Jie, Bu, Weiquan, Feng, Bin, Zhang, Meng, Luo, Yi, Jia, Xiaobin, Feng, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894619/
https://www.ncbi.nlm.nih.gov/pubmed/35234063
http://dx.doi.org/10.1177/15347354221078888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894619/
https://www.ncbi.nlm.nih.gov/pubmed/35234063
http://dx.doi.org/10.1177/15347354221078888

Ejemplares similares